Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibrutinib,Venetoclax

            Therapeutic Area: Oncology Product Name: Imbruvica

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 05, 2020

            Details:

            The results show the ibrutinib plus venetoclax combination providing continued disease-free survival for CLL patients once treatment is complete.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Venetoclax,Ibrutinib

            Therapeutic Area: Oncology Product Name: Venclexta

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            AbbVie will present updated results from the CAPTIVATE study, evaluating disease-free survival in previously untreated patients with chronic lymphocyctic leukemia/small lymphocytic leukemia who received ibrutinib (IMBRUVICA®) + venetoclax (VENCLEXTA®/ VENCLYXTO®) regimen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daunorubicin,Cytarabine,Venetoclax

            Therapeutic Area: Oncology Product Name: Vyxeos

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            Three abstracts selected for oral presentation, including long-term results from a Phase 3 study of Vyxeos in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mocravimod

            Therapeutic Area: Oncology Product Name: KRP203

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Fountain Healthcare

            Deal Size: $35.4 million Upfront Cash: Undisclosed

            Deal Type: Series A financing October 12, 2020

            Details:

            Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogenic hematopoietic stem cell transplantation (HSCT) for treating AML.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALKS 4230

            Therapeutic Area: Oncology Product Name: ALKS 4230

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 19, 2020

            Details:

            ALKS 4230 is an investigational, engineered fusion protein designed to selectively expand tumor-killing immune cells while avoiding the interleukin-2-induced activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex.